Published in Dermatoendocrinol on October 01, 2011
Race and Melanocortin 1 Receptor Polymorphism R163Q Are Associated with Post-Burn Hypertrophic Scarring: A Prospective Cohort Study. J Invest Dermatol (2015) 0.83
Hormones and skin: A never ending love story! Dermatoendocrinol (2011) 0.75
Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell (1993) 5.00
Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet (1995) 4.97
Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med (1982) 4.48
Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function. Cell (1993) 3.84
Melanocortin 1 receptor variants in an Irish population. J Invest Dermatol (1998) 2.70
MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer (2008) 2.37
Melanocortin-1 receptor structure and functional regulation. Pigment Cell Res (2005) 1.94
Interactive effects of MC1R and OCA2 on melanoma risk phenotypes. Hum Mol Genet (2004) 1.75
Characterization of melanocyte stimulating hormone receptor variant alleles in twins with red hair. Hum Mol Genet (1997) 1.70
Keloids: a review of the literature. Br J Plast Surg (1990) 1.66
alpha-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes. Cancer Res (2005) 1.58
Binding of melanotropic hormones to the melanocortin receptor MC1R on human melanocytes stimulates proliferation and melanogenesis. Endocrinology (1996) 1.52
Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants. Arch Dermatol (2007) 1.47
Mitogenic and melanogenic stimulation of normal human melanocytes by melanotropic peptides. Proc Natl Acad Sci U S A (1995) 1.42
Functional variation of MC1R alleles from red-haired individuals. Hum Mol Genet (2001) 1.38
New aspects on the melanocortins and their receptors. Pharmacol Res (2000) 1.35
Altered cell surface expression of human MC1R variant receptor alleles associated with red hair and skin cancer risk. Hum Mol Genet (2005) 1.30
Agouti signaling protein inhibits melanogenesis and the response of human melanocytes to alpha-melanotropin. J Invest Dermatol (1997) 1.26
Skin colour and skin cancer - MC1R, the genetic link. Melanoma Res (2002) 1.24
Melanocortin 1 receptor genotype: an important determinant of the damage response of melanocytes to ultraviolet radiation. FASEB J (2010) 1.23
Human DNA sequence variation in a 6.6-kb region containing the melanocortin 1 receptor promoter. Genetics (2001) 1.20
Human melanocortin 1 receptor variants, receptor function and melanocyte response to UV radiation. J Cell Sci (2002) 1.19
Dimerization of the human melanocortin 1 receptor: functional consequences and dominant-negative effects. J Invest Dermatol (2006) 1.12
alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: melanocortin peptides as a novel treatment strategy for scleroderma? Arthritis Rheum (2009) 1.06
Characterization of the promoter region of the human melanocortin-1 receptor (MC1R) gene. Biochem Biophys Res Commun (1999) 1.05
Melanocortin-1-receptor gene and sun sensitivity in individuals without red hair. Lancet (2000) 1.05
Does keloid pathogenesis hold the key to understanding black/white differences in hypertension severity? Hypertension (1995) 1.04
Aberrant trafficking of human melanocortin 1 receptor variants associated with red hair and skin cancer: Steady-state retention of mutant forms in the proximal golgi. J Cell Physiol (2009) 1.03
Collagen metabolism is a novel target of the neuropeptide alpha-melanocyte-stimulating hormone. J Biol Chem (2003) 1.02
Melanocortin receptor 1 variants and melanoma risk: a study of 2 European populations. Int J Cancer (2009) 0.97
Screening of human primary melanocytes of defined melanocortin-1 receptor genotype: pigmentation marker, ultrastructural and UV-survival studies. Pigment Cell Res (2003) 0.94
Ethnic disparities among patients with pulmonary hypertension associated with systemic sclerosis. J Rheumatol (2007) 0.94
Mapping of the gene encoding the melanocortin-1 (alpha-melanocyte stimulating hormone) receptor (MC1R) to human chromosome 16q24.3 by Fluorescence in situ hybridization. Genomics (1994) 0.92
Alpha-melanocyte-stimulating hormone and endothelin-1 have opposing effects on melanocyte adhesion, migration, and pp125FAK phosphorylation. Exp Cell Res (1997) 0.90
Functional MC1R-gene variants are associated with increased risk for severe photoaging of facial skin. J Invest Dermatol (2009) 0.89
Mapping of the ACTH, MSH, and neural (MC3 and MC4) melanocortin receptors in the mouse and human. Mamm Genome (1994) 0.89
Melanocortins in fibroblast biology--current update and future perspective for dermatology. Exp Dermatol (2004) 0.86
Unexpectedly severe acute radiotherapy side effects are associated with single nucleotide polymorphisms of the melanocortin-1 receptor. Int J Radiat Oncol Biol Phys (2009) 0.85
Melanocyte-stimulating hormone: a regulator of human melanocyte physiology. Pathobiology (1995) 0.83
Alpha-melanocyte stimulating hormone cytoprotective biology in human dermal fibroblast cells. Peptides (2005) 0.82
Melanocyte stimulating hormone induces the differentiation of mouse epidermal melanocytes in serum-free culture. J Cell Physiol (1992) 0.80
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol (2005) 3.04
Autocrine formation of hepcidin induces iron retention in human monocytes. Blood (2007) 2.50
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood (2009) 2.41
Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem (2004) 2.17
Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients. Cancer Immunol Immunother (2004) 2.12
Cutaneous amyloidoses and systemic amyloidoses with cutaneous involvement. Eur J Dermatol (2010) 2.03
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci U S A (2007) 1.97
The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res (2009) 1.90
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res (2006) 1.86
Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest (2006) 1.78
Safety and tolerability of adjuvant topical tacrolimus treatment in boys with lichen sclerosus: a prospective phase 2 study. Eur Urol (2008) 1.65
Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood (2011) 1.63
KITLG mutations cause familial progressive hyper- and hypopigmentation. J Invest Dermatol (2011) 1.59
Seborrheic keratosis. J Dtsch Dermatol Ges (2008) 1.49
The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism. Cell Metab (2014) 1.47
Granulomatous jellyfish dermatitis. J Dtsch Dermatol Ges (2007) 1.43
Recent advances in betalain research. Phytochemistry (2003) 1.41
Dysplastic melanocytic nevi of the lower leg: sex- and site-specific histopathology. Am J Dermatopathol (2010) 1.40
Absence of functional Hfe protects mice from invasive Salmonella enterica serovar Typhimurium infection via induction of lipocalin-2. Blood (2009) 1.40
Gene expression profiling of melanocytes following Q-Switched Ruby laser irradiation. Dermatology (2008) 1.37
High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J Invest Dermatol (2006) 1.37
High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer (2010) 1.32
Serum CRP and IL-6, genetic variants and risk of colorectal adenoma in a multiethnic population. Cancer Causes Control (2010) 1.28
Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res (2003) 1.28
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol (2005) 1.27
Occurence and clinical predictors of spasticity after ischemic stroke. Stroke (2010) 1.24
Pyoderma gangrenosum: clinical presentation and outcome in 18 cases and review of the literature. J Dtsch Dermatol Ges (2007) 1.24
RBP2-H1/JARID1B is a transcriptional regulator with a tumor suppressive potential in melanoma cells. Int J Cancer (2008) 1.22
Relationship between tobacco control policies and the delivery of smoking cessation services in nonprofit HMOs. J Natl Cancer Inst Monogr (2005) 1.22
Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. Mod Pathol (2006) 1.20
In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells. Cancer Biol Ther (2007) 1.18
Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood (2006) 1.18
Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas. Mod Pathol (2005) 1.16
Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases. Am J Clin Dermatol (2008) 1.16
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J Clin Oncol (2010) 1.14
Spectrum of FGFR3 mutations in multiple intraindividual seborrheic keratoses. J Invest Dermatol (2007) 1.13
Differential biological effects of 1,25-dihydroxyVitamin D3 on melanoma cell lines in vitro. J Steroid Biochem Mol Biol (2004) 1.12
Orofacial granulomatosis as the initial presentation of Crohn's disease in an adolescent. Dermatology (2003) 1.12
Re-expression of the retinoblastoma-binding protein 2-homolog 1 reveals tumor-suppressive functions in highly metastatic melanoma cells. J Invest Dermatol (2006) 1.10
Characterization of the vitamin D endocrine system in human sebocytes in vitro. J Steroid Biochem Mol Biol (2008) 1.08
Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease. Gastroenterology (2008) 1.07
A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. PLoS One (2012) 1.07
The spectrum of reticulate pigment disorders of the skin revisited. Eur J Dermatol (2012) 1.06
Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma. PPAR Res (2009) 1.06
Loss of EphB6 expression in metastatic melanoma. Int J Oncol (2003) 1.06
Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial. Melanoma Res (2007) 1.06
Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol (2008) 1.05
Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res (2007) 1.04
Growth differentiation factor 15 in anaemia of chronic disease, iron deficiency anaemia and mixed type anaemia. Br J Haematol (2009) 1.03
L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma. Cancer Lett (2003) 1.03
Activation of vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling pathways through 1,25(OH)(2)D(3) in melanoma cell lines and other skin-derived cell lines. Dermatoendocrinol (2009) 1.03
Vitamin D receptor (VDR) polymorphisms and skin cancer: A systematic review. Dermatoendocrinol (2011) 1.02
A novel Mg(2+)-dependent O-methyltransferase in the phenylpropanoid metabolism of Mesembryanthemum crystallinum. J Biol Chem (2003) 1.02
Pressure-induced volume expansion of zeolites in the natrolite family. J Am Chem Soc (2002) 1.01
Severe nail changes due to Docetaxel treatment. Eur J Dermatol (2004) 1.00
FGFR3 mutations in benign skin tumors. Cell Cycle (2006) 1.00
Changing a concept--controversy on the confusing spectrum of the reticulate pigmented disorders of the skin. J Cutan Pathol (2008) 1.00
Analysis of the vitamin D system in cutaneous squamous cell carcinomas. J Cutan Pathol (2004) 1.00
Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. Proc Natl Acad Sci U S A (2010) 1.00
Ephrin-B2 overexpression enhances integrin-mediated ECM-attachment and migration of B16 melanoma cells. Int J Oncol (2005) 0.99
Pathways for the regulation of hepcidin expression in anemia of chronic disease and iron deficiency anemia in vivo. Haematologica (2011) 0.99
Biochemical and structural analysis of substrate promiscuity in plant Mg2+-dependent O-methyltransferases. J Mol Biol (2008) 0.99
IgE-mediated anaphylactic reaction induced by succinate ester of methylprednisolone. Ann Allergy Asthma Immunol (2002) 0.99
Bilateral multifocal chorioretinopathy in a woman with cutaneous malignant melanoma. Arch Ophthalmol (2002) 0.99
Analysis of the vitamin D system in basal cell carcinomas (BCCs). Lab Invest (2004) 0.98
Screening rarely screened women: time-to-service and 24-month outcomes of tailored interventions. Prev Med (2003) 0.98
Structure of V(2)O(5)*nH(2)O xerogel solved by the atomic pair distribution function technique. J Am Chem Soc (2002) 0.98
Phenylpropanoid polyamine conjugate biosynthesis in Arabidopsis thaliana flower buds. Phytochemistry (2009) 0.97
Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer (2004) 0.97
Systems biology: a therapeutic target for tumor therapy. Cancer Microenviron (2008) 0.97
Ephrin-B2 is differentially expressed in the intestinal epithelium in Crohn's disease and contributes to accelerated epithelial wound healing in vitro. World J Gastroenterol (2005) 0.96
Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. Nephrol Dial Transplant (2010) 0.96
Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Res (2008) 0.96
Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Res (2008) 0.95
Analysis of vitamin D-receptor (VDR) and retinoid X-receptor alpha in breast cancer. Histochem J (2002) 0.95
FGFR3 mutations in epidermal nevi and seborrheic keratoses: lessons from urothelium and skin. J Invest Dermatol (2007) 0.95
25-hydroxyvitamin D deficiency in renal transplant recipients. J Clin Endocrinol Metab (2005) 0.95
Screening for iron overload: lessons from the hemochromatosis and iron overload screening (HEIRS) study. Can J Gastroenterol (2009) 0.95
1,25-dihydroxyvitamin D(3) protects human keratinocytes against UV-B-induced damage: In vitro analysis of cell viability/proliferation, DNA-damage and -repair. Dermatoendocrinol (2009) 0.94
Chiral three-dimensional microporous nickel aspartate with extended Ni-O-Ni bonding. J Am Chem Soc (2006) 0.94
Human endogenous retrovirus HERV-K(HML-2) proviruses with Rec protein coding capacity and transcriptional activity. Virology (2004) 0.94
ORAI1 Ca(2+) channels control endothelin-1-induced mitogenesis and melanogenesis in primary human melanocytes. J Invest Dermatol (2012) 0.94
New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARgamma agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy. Curr Cancer Drug Targets (2005) 0.94
Targeting T cells to hit B cells: successful treatment of cutaneous plasmacytosis with topical pimecrolimus. Dermatology (2006) 0.94
Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges (2008) 0.94
Progressive hyperpigmentation and generalized lentiginosis without associated systemic symptoms: a rare hereditary pigmentation disorder in south-east Germany. Acta Derm Venereol (2004) 0.94
Synthesis of orthorhombic Mo-V-Sb oxide species by assembly of pentagonal Mo6O21 polyoxometalate building blocks. Angew Chem Int Ed Engl (2009) 0.93
Recurring mixed-type neurothekeoma of the face. Dermatoendocrinol (2009) 0.93
Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology (2004) 0.93
Comparable effectiveness of endovenous laser ablation and high ligation with stripping of the great saphenous vein: two-year results of a randomized clinical trial (RELACS study). Arch Dermatol (2011) 0.92